Interactions between ibrutinib and anti-CD20 antibodies; competing effects on the outcome of combination therapy

PURPOSE: Clinical trials of ibrutinib combined with anti-CD20 monoclonal antibodies (mAbs) for chronic lymphocytic leukemia (CLL) report encouraging results. Paradoxically, in pre-clinical studies in vitro ibrutinib was reported to decrease CD20 expression and inhibits cellular effector mechanisms....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Skarzynski, Martin, Niemann, Carsten U, Lee, Yuh Shan, Martyr, Sabrina, Maric, Irina, Salem, Dalia, Stetler-Stevenson, Maryalice, Marti, Gerald E, Calvo, Katherine R, Yuan, Constance, Valdez, Janet, Soto, Susan, Farooqui, Mohammed Z.H., Herman, Sarah E.M., Wiestner, Adrian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4703510/
https://ncbi.nlm.nih.gov/pubmed/26283682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1304
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller